glp-1 receptor agonist kidney outcomes semaglutide flow trial 2024 results Effects of Once-Weekly on Disease by KDIGO Risk Category in the SUSTAIN 6 Cardiovascular, Kidney, and Safety Outcomes – The Role of Glucagon-Like Peptide-1

Inject the dose under the skin (subcutaneously) of the thigh, abdomen, or upper arm

Retatrutide may not be suitable for individuals who: Have severe gastrointestinal disorders Are pregnant or breastfeeding Have a history of pancreatitis Are currently on similar GLP-1 medications without supervision Always seek professional advice before starting any investigational medication

Phenylephrine or pseudoephedrine : Decongestants that may be included in some formulations

Do not give yourself extra medication or double your next dose unless you are told to do so

The financial sustainability of long-term use is a consideration

Even dehydration subtly reduces the medication's perceived effect, as thirst mimics hunger sensations